Effects of a Botanical Extract on Cognitive Performance and Cerebral Blood Flow in Healthy Adults
The Acute Effects of Sideritis Scardica (Greek Mountain Tea) on Cognitive Performance and Cerebral Blood Flow in Healthy Adults
The goal of this clinical trial is to learn how a study product affects cognitive performance and cerebral responses in adults. The study will also collect information about the safety of the study product. Participants will attend a screening visit followed by two study visits. During the study visits, participants will complete computerized cognitive assessments before and after consuming the study product and will wear a NIRS headband to record cerebral responses. Researchers will also monitor participants for adverse events and changes in medications or supplements during the study.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
This clinical trial investigates the acute effects of a Sideritis scardica study product on cognitive performance and cerebral responses during cognitive tasks in adults.
Participants will undergo computerized cognitive assessments together with near infrared spectroscopy (NIRS) recording before and after consumption of the study product. Cognitive testing includes choice reaction time (CRT) and rapid visual information processing (RVIP) tasks. NIRS recording is performed during the assessment periods to characterize cerebral responses associated with cognitive task performance.
Following screening, eligible participants will attend two intervention visits. The first intervention visit represents Day 1, and the second is scheduled approximately 8 days later. At each visit, cognitive and NIRS assessments are performed before study product consumption and are repeated after consumption. Standardized resting NIRS recording periods are incorporated into the assessment sequence.
Adverse events and relevant changes in medical conditions, medications, and supplements will be monitored throughout the study.
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 해당 없음
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Cynthia G. Suarez, PhD.
- 전화번호: +4916098144462
- 이메일: cynthia.suarez-rizzo@martin-bauer.com
연구 장소
-
-
RLP
-
Andernach, RLP, 독일, 56626
- Finzelberg
-
-
-
-
-
Cork, 아일랜드
- Atlantia Clinical Trials
-
연락하다:
- Scientific Director
- 전화번호: 7442 +353 (0) 021-430
- 이메일: krea@atlantiatrials.com
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Be able to give written informed consent.
- Be between 18-70 years of age.
- BMI between 18.5 and 30.0 kg/m2
- Willing to refrain from consuming alcohol for 24 h, non-habitual stimulants for 18 h prior to Visit 2 (Day 1) and Visit 3 (Day 8).
- Willing and able to comply with all study procedures and consume the study product as instructed at each study visit.
Exclusion Criteria:
-
Participants who are pregnant or wish to become pregnant during the study or who are lactating and/or currently breastfeeding.
-
Participants currently of biological childbearing potential but not using a continuous effective method of contraception as determined by the investigator.
-
Has a history of drug and/or alcohol abuse (within 12 months prior to visit 1)
-
Participants that are habitual smokers or vapers
-
High caffeine intake, >400mg/day (approximately equivalent to ≥4 cups of coffee per day
-
Has food allergies, or other issues with foods, that would preclude intake of the study products.
-
Has any significant acute or chronic coexisting health conditions that would prevent them from fulfilling the study requirements, put the Participant at risk or would confound the interpretation of the study results as judged by the investigator on the basis of medical history. Excluded health conditions include:
- Uncontrolled hypertension
- Clinically significant neurological or mental health conditions (history of stroke/TIA, epilepsy, traumatic brain injury with loss of consciousness, diagnosed ADHD, major depressive disorder within last 6 months)
- Diagnosed cognitive impairment
- Type I or II diabetes
- Clinically significant cardiovascular, liver and renal disease
- Diagnosed gastrointestinal conditions (IBD, coeliac disease)
-
Currently or recently taking a medication that the investigator believes would interfere with the objectives of the study or pose a safety risk or confound the interpretation of the study results as judged by the investigator. Prohibited medications include:
a) Prescription medications such a hypnotic, BDZs, antidepressants, antipsychotics, stimulants, beta-blockers, vasodilators, nootropics, and any psychoactive drugs (in the past 2 weeks prior to visit 1)
-
Current or recent (in the past 2 weeks) use of prohibited nutritional and non-nutritional supplements, that the investigator believes would interfere with the objectives of the study or pose a safety risk or confound the interpretation of the study results as judged by the investigator, including:
- Ginseng, ginkgo biloba, Luteolin, Apigenin supplements
- Products containing Sideritis, Sage, Thymus and Oregano
-
Individuals who, in the opinion of the investigator, are considered to be poor attendees or unlikely for any reason to be able to comply with the study.
-
Participants may not be participating in other clinical studies. If the participant has previously taken part in an experimental study, the Investigator must ensure sufficient time has elapsed before entry to this study to ensure the integrity of the results.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 방지
- 할당: 무작위
- 중재 모델: 크로스오버 할당
- 마스킹: 네 배로
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
위약 비교기: Placebo
Placebo supplement containing carrier material only |
Placebo supplement containing carrier material only |
|
실험적: Siderits
Sideritis supplement administered at an estimated daily dose |
Sideritis scardica preparation (Greek Mountain Tea) |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Difference between the Sideritis scardica (Greek Mountain Tea) extract, and placebo in the change from pre-dose assessment to the post-dose assessment period in Cognitive performance (Choice Reaction Time Task x 5 and RVIP x 1)
기간: Baseline, day 1, day 7
|
Evaluate the acute effects of Greek Mountain Tea extract, compared with placebo on Cognitive performance (Choice Reaction Time Task x 5 and RVIP x 1) |
Baseline, day 1, day 7
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Cognitive performance during the test called Choice Reaction Time (CRT)
기간: Baseline, day 1, day 7
|
Difference between Sideritis scardica (Greek Mountain Tea) extract and placebo in the change from pre-dose assessment in cognitive performance outcomes of Choice Reaction Time (CRT) with the measurement of following parameters: Choice Reaction Time accuracy, Choice Reaction Time (overall reaction time), Choice Reaction Time (correct response reaction time), Choice Reaction Time Number of Errors (%) |
Baseline, day 1, day 7
|
|
Cognitive Performance: Rapid Visual Information Processing (RVIP)
기간: Baseline, day 1, day 7
|
Difference between Sideritis scardica (Greek Mountain Tea) extract and placebo in the change from pre-dose assessment in cognitive performance outcomes of RVIP response time, RVIP false alarms, RVIP Number of Correct Detections (Hits) |
Baseline, day 1, day 7
|
|
Cerebral total haemoglobin approximately 150 to 240 minutes after administration
기간: Baseline, day 1, day 7, approximately 150 to 240 minutes after administration
|
Cerebral oxygenation as assessed by near-infrared spectroscopy (NIRS) analysis to determine total haemoglobin. |
Baseline, day 1, day 7, approximately 150 to 240 minutes after administration
|
|
Cerebral oxygenation
기간: Baseline, day 1, day 7, approximately 150 to 240 minutes after administration
|
Cerebral oxygenation assessed by near-infrared spectroscopy (NIRS) analysis, concurrent changes in tissue saturation index to determine total oxygen saturation. |
Baseline, day 1, day 7, approximately 150 to 240 minutes after administration
|
|
Cerebral oxygenated haemoglobin (HbO2) approximately 150 to 240 minutes after administration
기간: Baseline, day 1, day 7, approximately 150 to 240 minutes after administration
|
Cerebral oxygenation assessed by near-infrared spectroscopy (NIRS) analysis to determine oxygenated haemoglobin (HbO2) levels. |
Baseline, day 1, day 7, approximately 150 to 240 minutes after administration
|
|
Cerebral deoxygenated hemoglobin (HHb) approximately 150 to 240 minutes after administration
기간: Baseline, day 1, day 7, approximately 150 to 240 minutes after administration
|
Cerebral oxygenation assessed by near-infrared spectroscopy (NIRS) analysis to determinedeoxygenated hemoglobin (HHb) levels. |
Baseline, day 1, day 7, approximately 150 to 240 minutes after administration
|
공동 작업자 및 조사자
협력자
협력자
간행물 및 유용한 링크
일반 간행물
- Heiner F, Feistel B, Wink M. Sideritis scardica extracts inhibit aggregation and toxicity of amyloid-beta in Caenorhabditis elegans used as a model for Alzheimer's disease. PeerJ. 2018 Apr 30;6:e4683. doi: 10.7717/peerj.4683. eCollection 2018.
- Wightman EL, Jackson PA, Khan J, Forster J, Heiner F, Feistel B, Suarez CG, Pischel I, Kennedy DO. The Acute and Chronic Cognitive and Cerebral Blood Flow Effects of a Sideritis scardica (Greek Mountain Tea) Extract: A Double Blind, Randomized, Placebo Controlled, Parallel Groups Study in Healthy Humans. Nutrients. 2018 Jul 24;10(8):955. doi: 10.3390/nu10080955.
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- FB_AF216
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
The IPD dataset will include de-identified participant-level demographic and baseline characteristics, treatment allocation, and individual results for the primary and secondary outcome measures included in the published analyses. Derived variables necessary to reproduce the reported statistical analyses may also be included. Direct identifiers and other information that could reasonably permit participant identification will not be shared.
IPD 공유 기간
Start date: Following completion of the study and publication of the primary study results.
End date: Available thereafter upon reasonable request, subject to applicable data-retention requirements and sponsor policies.
IPD 공유 액세스 기준
Qualified researchers may request access to de-identified IPD underlying the reported results and relevant supporting documents. Requests must include a scientifically sound proposal and will be reviewed by the study sponsor/data custodian. Approved applicants will receive only the data necessary for the approved purpose through an appropriate secure data-sharing mechanism and, where applicable, under a data-use agreement. No directly identifiable participant information will be shared.
IPD 공유 지원 정보 유형
- 연구_프로토콜
- ICF
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .